XORTX Therapeutics Inc., a company specializing in innovative treatments for gout and progressive kidney disease, is set to proceed with its share consolidation plan on April 6, 2026. The consolidation will involve exchanging five old common shares for one new common share. This decision, which follows a previous announcement on March 26, 2026, has received approvals from both the TSX Venture Exchange and Nasdaq Stock Exchange. The company's stock is listed under tickers XRTX on NASDAQ, XRTX on TSX Venture, and ANU on Frankfurt.